Product Description
Tarsus Pharmaceuticals is developing Lotilaner as a treatment for meibomian gland disease (MGD). (Sourced from: https://tarsusrx.com/pipeline/tp-03/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | European Medicines Agency | Norway | Poland
Approved Indications: None
Known Adverse Events: None
Company: Tarsus Pharmaceuticals
Company Location: IRVINE CA 92618
Company CEO: Bobak Azamian
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Blepharitis
Phase 2: Meibomian Gland Dysfunction|Rosacea
Phase 1: Vision, Low
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Rhea | P2 |
Active, not recruiting |
Meibomian Gland Dysfunction|Blepharitis |
2024-06-15 |
24% |
| TRS-016 | P2 |
Completed |
Rosacea |
2023-11-13 |
24% |
| LB4001-301 | P3 |
Completed |
Blepharitis |
2023-09-15 |
|
| Ersa | P2 |
Completed |
Meibomian Gland Dysfunction|Blepharitis |
2023-05-18 |
24% |